24 results on '"Bagga, Arvind"'
Search Results
2. Haemolytic uraemic syndrome.
- Author
-
Michael M, Bagga A, Sartain SE, and Smith RJH
- Subjects
- Humans, Hemolytic-Uremic Syndrome diagnosis, Hemolytic-Uremic Syndrome therapy, Hemolytic-Uremic Syndrome etiology, Thrombotic Microangiopathies diagnosis, Thrombotic Microangiopathies etiology, Thrombotic Microangiopathies therapy, Acute Kidney Injury etiology, Acute Kidney Injury therapy
- Abstract
Haemolytic uraemic syndrome (HUS) is a heterogeneous group of diseases that result in a common pathology, thrombotic microangiopathy, which is classically characterised by the triad of non-immune microangiopathic haemolytic anaemia, thrombocytopenia, and acute kidney injury. In this Seminar, different causes of HUS are discussed, the most common being Shiga toxin-producing Escherichia coli HUS. Identifying the underlying thrombotic microangiopathy trigger can be challenging but is imperative if patients are to receive personalised disease-specific treatment. The quintessential example is complement-mediated HUS, which once carried an extremely high mortality but is now treated with anti-complement therapies with excellent long-term outcomes. Unfortunately, the high cost of anti-complement therapies all but precludes their use in low-income countries. For many other forms of HUS, targeted therapies are yet to be identified., Competing Interests: Declaration of interests MM declares no conflicts of interest related to this topic but has served as site principal investigator for use of lumasiran for primary hyperoxaluria type 1 by Alnylam Pharmaceuticals. SES has received research funding from Alexion Pharmaceuticals to test pre-clinical complement agents in murine models of complement-mediated disease. RJHS directs the Molecular Otolaryngology and Renal Research Laboratories (Iowa City, IA, USA) where genetic and complement testing for atypical HUS and the TMAs is done. AB declares no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
3. Guidelines on Hemolytic Uremic Syndrome by Indian Society of Pediatric Nephrology: Key Messages.
- Author
-
Khandelwal P and Bagga A
- Subjects
- Child, Consensus, Humans, Renal Dialysis, Acute Kidney Injury, Hemolytic-Uremic Syndrome diagnosis, Hemolytic-Uremic Syndrome therapy, Nephrology
- Abstract
Hemolytic uremic syndrome is an important cause of acute kidney injury that requires dialysis in children. The diagnosis and management is difficult due to limited diagnostic facilities and non-availability of specific complement inhibitors. We describe salient features of the recent Indian Society of Pediatric Nephrology consensus guidelines on hemolytic uremic syndrome.
- Published
- 2020
4. Hemolytic uremic syndrome in a developing country: Consensus guidelines.
- Author
-
Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, and Dragon-Durey MA
- Subjects
- Consensus, Developing Countries, Hemolytic-Uremic Syndrome drug therapy, Hemolytic-Uremic Syndrome immunology, Hemolytic-Uremic Syndrome microbiology, Humans, India, Nephrology methods, Plasma Exchange, Shiga-Toxigenic Escherichia coli isolation & purification, Consensus Development Conferences as Topic, Hemolytic-Uremic Syndrome diagnosis, Nephrology standards, Practice Guidelines as Topic, Shiga-Toxigenic Escherichia coli immunology
- Abstract
Background: Hemolytic uremic syndrome (HUS) is a leading cause of acute kidney injury in children. Although international guidelines emphasize comprehensive evaluation and treatment with eculizumab, access to diagnostic and therapeutic facilities is limited in most developing countries. The burden of Shiga toxin-associated HUS in India is unclear; school-going children show high prevalence of anti-factor H (FH) antibodies. The aim of the consensus meeting was to formulate guidelines for the diagnosis and management of HUS in children, specific to the needs of the country., Methods: Four workgroups performed literature review and graded research studies addressing (i) investigations, biopsy, genetics, and differential diagnosis; (ii) Shiga toxin, pneumococcal, and infection-associated HUS; (iii) atypical HUS; and (iv) complement blockade. Consensus statements developed by the workgroups were discussed during a consensus meeting in March 2017., Results: An algorithm for classification and evaluation was developed. The management of Shiga toxin-associated HUS is supportive; prompt plasma exchanges (PEX) is the chief therapy in patients with atypical HUS. Experts recommend that patients with anti-FH-associated HUS be managed with a combination of PEX and immunosuppressive medications. Indications for eculizumab include incomplete remission with plasma therapy, life-threatening features, complications of PEX or vascular access, inherited defects in complement regulation, and recurrence of HUS in allografts. Priorities for capacity building in regional and national laboratories are highlighted., Conclusions: Limited diagnostic capabilities and lack of access to eculizumab prevent the implementation of international guidelines for HUS in most developing countries. We propose practice guidelines for India, which will perhaps be applicable to other developing countries.
- Published
- 2019
- Full Text
- View/download PDF
5. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.
- Author
-
Khandelwal P, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, and Bagga A
- Subjects
- Child, Combined Modality Therapy, Female, Hemolytic-Uremic Syndrome immunology, Humans, Immunosuppressive Agents therapeutic use, Male, Retrospective Studies, Treatment Outcome, Autoantibodies blood, Complement Factor H immunology, Hemolytic-Uremic Syndrome blood, Hemolytic-Uremic Syndrome drug therapy, Plasma Exchange
- Abstract
Background: Anti-complement factor H (anti-CFH) antibody-associated hemolytic uremic syndrome (HUS) is an important cause of acute kidney injury in Indian children. While management comprises plasma exchange and immunosuppression, information on the impact on serial antibody titers and outcomes is limited., Methods: This retrospective study included 45 patients with anti-CFH-associated HUS who were followed for ≥12 months. Following the initial plasma exchange sessions, patients received prednisolone and either intravenous (IV) cyclophosphamide (n = 31) or IV rituximab (n = 14), followed by maintenance immunosuppression., Results: The median anti-CFH antibody titers fell from 3,215.5 [interquartile range (IQR) 1,977.9-8,453.9 to 414.6 (IQR 251.6-1,368.2) AU/ml with plasma exchange therapy (P < 0.0001), and the decline was similar with three, five, or seven plasma exchange sessions (P = 0.08). Serial anti-CFH titers were similar in patients receiving IV cyclophosphamide- and rituximab-based regimens during the 12-month follow-up (P = 0.63). Renal outcomes and relapse frequencies at the 15.4-month follow-up were comparable. Seven patients relapsed 6.5 (IQR 2.2-12.3) months from treatment onset. Patients with relapse had higher antibody titers during remission (P = 0.017). Titers of ≥1,300 AU/ml at 6 months predicted subsequent relapses., Conclusions: Our patients with anti-CFH antibody-associated HUS showed a significant fall in antibody titers following daily plasma exchange sessions. Therapy with cyclophosphamide- or rituximab-based regimens was associated with similar outcomes and a comparable decline in antibody titers.
- Published
- 2015
- Full Text
- View/download PDF
6. Plasma exchanges and immunosuppression for anti-complement factor H associated hemolytic uremic syndrome.
- Author
-
Khandelwal P, Sinha A, Hari P, and Bagga A
- Subjects
- Adrenal Cortex Hormones therapeutic use, Autoantibodies, Child, Child, Preschool, Complement Factor H antagonists & inhibitors, Female, Humans, Kidney Failure, Chronic, Male, Hemolytic-Uremic Syndrome therapy, Immunosuppressive Agents therapeutic use, Plasma Exchange
- Abstract
Background: Atypical hemolytic uremic syndrome associated with autoantibodies to complement factor H is an important cause of acute kidney injury; most patients require dialysis and are at risk of progressive renal failure., Case Characteristics: 7 patients with gastrointestinal symptoms, acute kidney injury, thrombotic microangiopathy and elevated levels of anti-complement factor H antibodies., Intervention: Prompt initiation of plasma exchanges and immunosuppression., Outcome: Remission of hematological and kidney functions., Message: Prompt and specific management of antibody associated hemolytic uremic syndrome is associated with favorable outcome.
- Published
- 2014
7. Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome.
- Author
-
Khandelwal P, Sinha A, Hari P, Bansal VK, Dinda AK, and Bagga A
- Subjects
- Adolescent, Antibodies, Monoclonal, Murine-Derived therapeutic use, Child, Humans, Immunosuppressive Agents therapeutic use, Male, Plasma Exchange methods, Recurrence, Renal Insufficiency surgery, Rituximab, Time Factors, Treatment Outcome, Autoantibodies blood, Complement Factor H immunology, Hemolytic-Uremic Syndrome immunology, Hemolytic-Uremic Syndrome therapy, Immunoglobulins, Intravenous therapeutic use, Kidney Transplantation
- Abstract
Atypical HUS associated with anti-CFH autoantibodies is an uncommon illness associated with high risk of progression to end-stage renal disease. Disease relapses after transplantation, observed in one-third cases, often lead to graft loss. We report four patients with anti-CFH antibody-associated HUS who underwent renal transplantation 16-62 months from initial presentation. Two patients each received organs from deceased and living-related donors. Anti-CFH antibody titers were monitored during the illness and following transplantation. All patients received two doses of IV rituximab before or after transplantation; three patient each received 1-2 g/kg of IV immunoglobulin or underwent 2-5 sessions of plasma exchanges. The use of therapeutic plasma exchange, IV immunoglobulin, and rituximab in two cases enabled two-third reduction in anti-CFH antibody titers before transplantation. At 5- to 26-month follow-up, all patients showed satisfactory graft function without recurrence of HUS. This is the first report of patients with anti-CFH antibody-associated HUS who underwent living-related renal transplantation. Clearance of anti-CFH antibody by therapeutic plasma exchange and adjuvant immunosuppression aimed at decreasing antibody levels may enable successful transplantation and recurrence-free survival., (© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
8. Therapy for patients with antibodies to complement factor H associated HUS.
- Author
-
Bagga A, Sinha A, and Dragon-Durey MA
- Subjects
- Female, Humans, Male, Antibodies, Monoclonal, Humanized therapeutic use, Hemolytic-Uremic Syndrome drug therapy
- Published
- 2014
- Full Text
- View/download PDF
9. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.
- Author
-
Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, and Bagga A
- Subjects
- Age Factors, Antibodies, Monoclonal, Murine-Derived therapeutic use, Azathioprine therapeutic use, Biomarkers blood, Blood Proteins genetics, Case-Control Studies, Child, Child, Preschool, Combined Modality Therapy, Complement C3b Inactivator Proteins genetics, Cyclophosphamide therapeutic use, Drug Therapy, Combination, Female, Gene Deletion, Hemolytic-Uremic Syndrome blood, Hemolytic-Uremic Syndrome diagnosis, Hemolytic-Uremic Syndrome genetics, Hemolytic-Uremic Syndrome immunology, Homozygote, Humans, Immunosuppressive Agents adverse effects, India, Infant, Male, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid therapeutic use, Prednisolone therapeutic use, Recurrence, Risk Factors, Rituximab, Time Factors, Treatment Outcome, Autoantibodies blood, Blood Proteins immunology, Complement C3b Inactivator Proteins immunology, Hemolytic-Uremic Syndrome therapy, Immunosuppressive Agents therapeutic use, Plasma Exchange adverse effects, Time-to-Treatment
- Abstract
Antibodies to complement factor H are an uncommon cause of hemolytic uremic syndrome (HUS). Information on clinical features and outcomes in children is limited. In order to explore this we studied a multicenter cohort of 138 Indian children with anti-complement factor H antibody associated HUS, constituting 56% of patients with HUS. Antibody titers were high (mean 7054 AU/ml) and correlated inversely with levels of complement C3, but not complement factor H. Homozygous deletion of the CFHR1 gene was found in 60 of 68 patients. Therapies included dialysis in 119 children, 105 receiving plasma exchanges and 26 intravenous immunoglobulin. Induction immunosuppression consisted of 87 children receiving prednisolone with or without intravenous cyclophosphamide or rituximab. Antibody titers fell significantly following plasma exchanges and increased during relapses. Adverse outcome (stage 4-5 CKD or death) was seen in 36 at 3 months and 41 by last follow up, with relapse in 14 of 122 available children. Significant independent risk factors for adverse outcome were an antibody titer over 8000 AU/ml, low C3 and delay in plasma exchange. Combined plasma exchanges and induction immunosuppression resulted in significantly improved renal survival: one adverse outcome prevented for every 2.6 patients treated. Maintenance immunosuppressive therapy, of prednisolone with either mycophenolate mofetil or azathioprine, significantly reduced the risk of relapses. Thus, prompt use of immunosuppressive agents and plasma exchanges are useful for improving outcomes in pediatric patients with anti-complement factor H-associated HUS.
- Published
- 2014
- Full Text
- View/download PDF
10. Peripheral gangrene in children with atypical hemolytic uremic syndrome.
- Author
-
Malina M, Gulati A, Bagga A, Majid MA, Simkova E, and Schaefer F
- Subjects
- Atypical Hemolytic Uremic Syndrome, Child, Preschool, Fatal Outcome, Female, Gangrene complications, Gangrene diagnosis, Humans, Infant, Fingers pathology, Hemolytic-Uremic Syndrome complications, Hemolytic-Uremic Syndrome diagnosis, Toes pathology
- Abstract
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy with severe clinical manifestation, frequent recurrence, and poor long-term prognosis. It is usually caused by abnormalities in complement regulation. We report 2 cases of children affected by a catastrophic extrarenal complication. A 4-year-old Indian girl developed gangrene of the finger tips 2 days after initial presentation of aHUS. Factor H autoantibodies were identified. Renal function continued to decline despite daily plasma exchanges, and she was started on peritoneal dialysis 5 days after admission. The distal tips of the left hand remained gangrenous with a line of demarcation. Three weeks later, she did not return for follow-up and died at home because of dialysis-related complications. An Arabic girl developed end-stage renal disease due to aHUS in the fourth month after birth. A de novo activating C3 mutation was found. At age 9 months, she suddenly developed ischemic changes in fingers of both hands and several toes. The lesions progressed, and several finger tips became gangrenous despite intense plasma exchange therapy. The decision was made to administer complement blocking therapy with the C5 antibody eculizumab. All nonnecrotic digits rapidly regained perfusion. The 3 already gangrenous fingers healed with loss of the end phalanges. During maintenance, eculizumab aHUS activity subsided completely and some late recovery of renal function was observed. aHUS may present by thrombotic macroangiopathy of small peripheral arteries. Eculizumab appears effective in preserving tissue viability if administered before gangrene occurs and should be considered as first-line rescue therapy in such cases.
- Published
- 2013
- Full Text
- View/download PDF
11. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.
- Author
-
Blanc C, Roumenina LT, Ashraf Y, Hyvärinen S, Sethi SK, Ranchin B, Niaudet P, Loirat C, Gulati A, Bagga A, Fridman WH, Sautès-Fridman C, Jokiranta TS, Frémeaux-Bacchi V, and Dragon-Durey MA
- Subjects
- Acute Disease, Adult, Autoimmune Diseases diagnosis, Autoimmune Diseases pathology, Child, Complement C3 metabolism, Complement Factor H metabolism, Hemolytic-Uremic Syndrome diagnosis, Hemolytic-Uremic Syndrome pathology, Humans, Protein Binding immunology, Autoantibodies physiology, Autoimmune Diseases immunology, Complement Factor H antagonists & inhibitors, Complement Factor H immunology, Hemolytic-Uremic Syndrome immunology, Neutralization Tests methods
- Abstract
Complement is a major innate immune surveillance system. One of its most important regulators is the plasma protein factor H (FH). FH inactivation by mutations or by autoantibodies is associated with a thrombotic microangiopathy disease, atypical hemolytic uremic syndrome. In this study, we report the characterization of blood samples from 19 anti-FH Ab-positive atypical hemolytic uremic syndrome patients collected at the acute phase of the disease. Analyses of the functional consequences and epitope mapping, using both fluid phase and solid phase approaches, were performed. The anti-FH Abs perturbed FH-mediated cell protection (100%), inhibited FH interaction with C3 (46%), and caused C3 consumption (47%). The Abs were directed against multiple FH epitopes located at the N and C termini. In all tested patients, high titers of FH-containing circulating immune complexes were detected. The circulating immune complex titers correlated with the disease stage better than did the Ab titers. Our results show that anti-FH autoantibodies induce neutralization of FH at acute phase of the disease, leading to an overall impairment of several functions of FH, extending the role of autoantibodies beyond the impairment of the direct cell surface protection.
- Published
- 2012
- Full Text
- View/download PDF
12. Therapeutic plasmapheresis using membrane plasma separation.
- Author
-
Sinha A, Tiwari AN, Chanchlani R, Seetharamanjaneyulu V, Hari P, and Bagga A
- Subjects
- Adolescent, Atypical Hemolytic Uremic Syndrome, Child, Demyelinating Autoimmune Diseases, CNS therapy, Feasibility Studies, Female, Glomerulosclerosis, Focal Segmental therapy, Guillain-Barre Syndrome therapy, Humans, Lupus Erythematosus, Systemic therapy, Male, Plasmapheresis adverse effects, Plasmapheresis instrumentation, Treatment Outcome, Glomerulonephritis therapy, Hemolytic-Uremic Syndrome therapy, Plasmapheresis methods
- Abstract
The authors present their experience with therapeutic plasmapheresis (TPE) using membrane filters at the pediatric dialysis unit of a referral center. Between January 2006 and December 2010, 486 sessions of TPE were performed in 39 patients (range 6-17 y), chiefly for atypical hemolytic uremic syndrome (HUS, n = 22), crescentic glomerulonephritis (n = 8) and focal segmental glomerulosclerosis (n = 5). Satisfactory response was noted in 32 patients, particularly with HUS (n = 22) or crescentic glomerulonephritis (n = 6). Adverse effects included chills or urticaria (n = 8 sessions), hypocalcemia (n = 6) and hypotension (n = 5). The present findings highlight the safety, efficacy and feasibility of TPE using membrane filtration.
- Published
- 2012
- Full Text
- View/download PDF
13. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.
- Author
-
Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, and Frémeaux-Bacchi V
- Subjects
- Adult, Age Factors, Child, Child, Preschool, Cohort Studies, Complement Activation immunology, Female, Follow-Up Studies, Hemolytic-Uremic Syndrome diagnosis, Hemolytic-Uremic Syndrome epidemiology, Humans, Immunoglobulins, Intravenous administration & dosage, Infant, Kidney Transplantation, Male, Middle Aged, Plasma Exchange methods, Risk Assessment, Severity of Illness Index, Sex Factors, Stem Cell Transplantation methods, Time Factors, Treatment Outcome, Autoantibodies immunology, Complement Factor H immunology, Hemolytic-Uremic Syndrome immunology, Hemolytic-Uremic Syndrome therapy
- Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy that associates, in 70% of cases, with genetic or acquired disorders leading to dysregulation of the alternative pathway of complement. Autoantibody directed against Factor H causes at least 6% to 10% of aHUS cases, but only a few clinical reports are available. Here, we describe the clinical, biologic, genetic features, treatment, and outcome of 45 patients who presented with aHUS associated with anti-FH autoantibody. We found that this form of aHUS primarily affects children between 9 and 13 years old but it also affects adults. It presents with a high frequency of gastrointestinal symptoms and with extrarenal complications and has a relapsing course. Activation of the alternative pathway of complement at the onset of disease portends a poor prognosis. Early specific treatment may lead to favorable outcomes. These data should improve the recognition and diagnosis of this form of aHUS and help identify patients at high risk of a poor outcome.
- Published
- 2010
- Full Text
- View/download PDF
14. Hemolytic uremic syndrome due to homozygous factor H deficiency.
- Author
-
Sethi SK, Marie-Agnes DD, Thaker N, Hari P, and Bagga A
- Subjects
- Base Sequence, Complement C3 genetics, Complement C3 metabolism, Complement C4 genetics, Complement C4 metabolism, DNA Mutational Analysis, Female, Genetic Predisposition to Disease, Heterozygote, Humans, Infant, Kidney pathology, Male, Molecular Sequence Data, Complement Factor H deficiency, Complement Factor H genetics, Hemolytic-Uremic Syndrome etiology, Hemolytic-Uremic Syndrome genetics
- Abstract
The majority of complement factor H mutations associated with atypical hemolytic uremic syndrome (HUS) are heterozygous. Homozygous mutations causing atypical hemolytic uremic syndrome are rare. We report a 7-month-old boy with HUS, severe hypocomplementemia (low C3 and normal C4 levels), and extremely low circulating levels of factor H. Genetic analysis showed homozygous 4 bp deletion in the gene encoding factor H in the patient, with his parents being carriers. The patient showed progression to end-stage renal disease and is presently on chronic ambulatory peritoneal dialysis.
- Published
- 2009
- Full Text
- View/download PDF
15. Abbreviated protocol of plasma exchanges for patients with anti-factor H associated hemolytic uremic syndrome.
- Author
-
Thangaraju, Sharan, Khandelwal, Priyanka, Mishra, Kirtisudha, Kumar, Manish, Puraswani, Mamta, Saini, Rahul, Hari, Pankaj, Coshic, Poonam, Sinha, Aditi, and Bagga, Arvind
- Subjects
HEMOLYTIC-uremic syndrome treatment ,MEDICAL protocols ,RESEARCH funding ,AUTOANTIBODIES ,HEMOLYTIC-uremic syndrome ,DESCRIPTIVE statistics ,TREATMENT effectiveness ,DISEASE remission ,LONGITUDINAL method ,PLASMA exchange (Therapeutics) ,IMMUNOSUPPRESSION ,DISEASE risk factors - Abstract
Background: Plasma exchanges (PEX) and immunosuppression are the cornerstone of management of anti-factor H (FH) antibody-associated atypical hemolytic uremic syndrome (aHUS), particularly if access to eculizumab is limited. The duration of therapy with PEX for anti-FH aHUS is empirical. Methods: We compared the efficacy of abbreviated PEX protocol (10–12 sessions) in a prospective cohort of patients diagnosed with anti-FH aHUS (2020–2022), to standard PEX protocol (20–22 sessions) in a historical cohort (2016–2019; n = 65). Efficacy was defined as 70% decline in anti-FH titers or fall to ≤ 1300 AU/ml at 4 weeks. Patients in both cohorts received similar immunosuppression with oral prednisolone, IV cyclophosphamide (5 doses) and mycophenolate mofetil. Outcomes included efficacy, rates of hematological remission and adverse kidney outcomes at 1, 3 and 6 months. Results: Of 23 patients, 8.2 ± 2.1 years old enrolled prospectively, two were excluded for significant protocol deviation. PEX was abbreviated in 18/21 (86%) patients to 11.5 ± 3.3 sessions. Abbreviation failed for lack of hematological remission by day 14 (n = 2) and persistent neurological manifestations (n = 1). All patients in whom PEX was abbreviated achieved > 70% reduction in anti-FH titers at day 28. The percentage fall in anti-FH titers was similar for the abbreviated vs. standard PEX protocols at 1, 3 and 6 months. At last follow-up, at median 50 months and 25 months for standard and abbreviated cohorts, the estimated GFR was similar at 104.8 ± 29.1 vs. 93.7 ± 53.4, respectively (P = 0.42). Conclusion: Abbreviation of the duration of PEX is feasible and efficacious in reducing anti-FH titers. Short-term outcomes were comparable in patients managed by abbreviated and standard PEX protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Anti-factor B antibodies in atypical hemolytic uremic syndrome.
- Author
-
Khandelwal, Priyanka, Nambiar, Shreesha, Saini, Rahul, Saini, Savita, Coshic, Poonam, Sinha, Aditi, Hari, Pankaj, Palanichamy, Jayanth Kumar, and Bagga, Arvind
- Subjects
AUTOANTIBODY analysis ,IMMUNOGLOBULIN analysis ,RISK assessment ,RESEARCH funding ,ENZYME-linked immunosorbent assay ,HEMOGLOBINS ,HEMOLYTIC-uremic syndrome ,COMPLEMENT (Immunology) ,SEVERITY of illness index ,DESCRIPTIVE statistics ,GLOMERULONEPHRITIS ,GENETIC variation ,VOLUMETRIC analysis ,BLOOD platelets ,WESTERN immunoblotting ,CONFIDENCE intervals ,DISEASE relapse ,GENETICS - Abstract
Background: The etiology of atypical hemolytic uremic syndrome (aHUS) is unknown in 30–40% of patients. Anti-factor B (FB) antibodies are reported in C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN), though not in aHUS. Methods: We screened patients < 18-year-old from cohorts of aHUS and C3G/idiopathic IC-MPGN. Anti-FB IgG antibodies were measured by ELISA and confirmed by Western blot. Normative levels were based on antibody levels in 103 healthy blood donors. Results: Prevalence of anti-FB antibodies was 9.7% (95% CI 6.1–14.5%; n = 21) in 216 patients with aHUS, including 11.5% (95% CI 6.4–18.5%; n = 14) in anti-FH associated aHUS and 11.8% (95% CI 4.4–23.9%; n = 6) in patients without a definitive genetic or autoimmune etiology. Patients with significant genetic variants did not show anti-FB antibodies. In patients with concomitant anti-FB and anti-FH antibodies, median anti-FH titers were higher (11,312 AU/mL vs. 4920 AU/mL; P = 0.04). Anti-FB antibody titer correlated with disease severity (hemoglobin and platelets; P < 0.05), declined following plasma exchange and increased during relapse. While 4/64 patients with C3G (6.3%) and 1/17 with IC-MPGN showed anti-FB antibodies, titers were higher in aHUS (544.8 AU/mL vs. 1028.8 AU/mL; P = 0.003). Conclusion: Anti-FB antibodies are present in 6–10% of patients with aHUS and C3G/IC-MPGN, with higher titers in the former. The diagnostic and therapeutic implication of anti-FB antibodies in aHUS needs confirmation and further studies. The study shows propensity for autoantibody generation and co-existence of multiple risk factors for aHUS in Indian children. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome.
- Author
-
Khandelwal, Priyanka, Joshi, Aditi, Mathur, Aradhana, Puraswani, Mamta, Gurjar, Bahadur Singh, Sinha, Aditi, Hari, Pankaj, Faruq, Mohammed, and Bagga, Arvind
- Subjects
HEMOLYTIC-uremic syndrome treatment ,AUTOANTIBODIES ,GLOMERULAR filtration rate ,COMPLEMENT (Immunology) ,SEQUENCE analysis ,CONFIDENCE intervals ,BLOOD plasma ,PLASMA exchange (Therapeutics) ,KIDNEY failure ,GENETIC variation ,IMMUNOSUPPRESSION ,TREATMENT effectiveness ,RESEARCH funding ,HEMOLYTIC-uremic syndrome ,DEATH ,LONGITUDINAL method - Abstract
Background: Coexisting genetic variants in patients with anti-factor H (FH)-associated atypical hemolytic uremic syndrome (aHUS) have implications for therapy. We estimated the prevalence of complement genetic variants in children with anti-FH aHUS from a prospective nationwide cohort and determined if significant genetic variants impact long-term kidney outcomes. Methods: Of 436 patients in the database, 77 consecutive patients, 21 with a relapse and 9 with kidney failure and/or death were included. Targeted sequencing, using a 27-gene panel including CFH, CFI, CFB, C3, CD46, PLG, DGKE, and THBD and multiplex ligation-dependent probe amplification of CFH-CFHR region, was performed. The adverse outcome was eGFR < 30 ml/min/1.73 m
2 or death. Results: Patients had high anti-FH titers 5670 (2177–13,545) AU/ml, relapsing course (42.1%), and adverse outcomes (19.6%). Variants, chiefly of unknown significance, were found in 7 (6.5%; 95% CI 3.1–13.2%); a pathogenic variant was found in one patient. Homozygous deletion of CFHR1 was present in 91.6% compared to 9.8% in 184 healthy controls. Plasma exchanges and immunosuppression showed a trend of improving outcomes, independent of genetic defects (HR 0.32; P = 0.070). Meta-analysis of 18 studies (384 patients) showed that the pooled prevalence of pathogenic and likely pathogenic variants was 3% (95% CI 0–8%). Of 37 total variants in the meta-analysis, 7 (18.9%) each were pathogenic and likely pathogenic; others were variants of unknown significance. Conclusions: Significant variants in complement regulatory genes are rare in patients with anti-FH-associated aHUS. Irrespective of genetic defects, plasma exchanges and immunosuppression showed a statistical trend to improved outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
18. Anti-factor H antibody associated hemolytic uremic syndrome following SARS-CoV-2 infection.
- Author
-
Khandelwal, Priyanka, Krishnasamy, Sudarsan, Govindarajan, Srinivasavaradan, Kumar, Manish, Marik, Binata, Sinha, Aditi, Hari, Pankaj, and Bagga, Arvind
- Subjects
DISEASE relapse ,HEMOLYTIC-uremic syndrome treatment ,AUTOANTIBODIES ,REVERSE transcriptase polymerase chain reaction ,RESPIRATORY diseases ,GLOMERULAR filtration rate ,COVID-19 ,FEVER ,GENETIC mutation ,PREDNISOLONE ,BLOOD transfusion ,GENETIC testing ,MYCOPHENOLIC acid ,CYCLOPHOSPHAMIDE ,HEMOLYTIC-uremic syndrome ,COVID-19 testing ,DISEASE risk factors ,THERAPEUTICS - Abstract
Background: The pathogenesis of autoantibody generation in anti-factor H (FH) antibody associated atypical hemolytic uremic syndrome (aHUS) is unknown and is perhaps triggered by an infectious or environmental agent. We observed an unusual increase of patients with anti-FH antibody associated aHUS coinciding with the second pandemic wave in New Delhi and suspected that SARS-CoV-2 infection might be a potential trigger. Methods: We screened for SARS-CoV-2 infection using reverse transcriptase polymerase chain reaction (RT-PCR) and serology in 13 consecutive patients with anti-FH antibody associated aHUS during the past year in New Delhi. Results: We report 5 patients, 4–13 years old, who presented with a febrile illness without respiratory symptoms during the second pandemic wave. Of these, 3 patients presented with a relapse 25–85 months following the initial episode of aHUS. SARS-CoV-2 was detected by RT-PCR in 1 patient and by serology in 4 patients (median titer 47.1 cut-off index). Patients had high titers of anti-FH antibodies (median 2,300 AU/ml). Genetic studies, done in 3 of the 5 patients, showed homozygous CFHR1 deletion without other significant genetic abnormalities. Specific management comprised plasma exchanges and oral prednisolone, combined with either cyclophosphamide or mycophenolate mofetil. At median follow-up of 3.3 months, the estimated glomerular filtration rate in 4 patients ranged from 62 to 110 ml/min/1.73 m
2 ; one patient was dialysis-dependent. Conclusion: Increased vigilance is required during the pandemic, especially in patients with anti-FH associated aHUS, who might relapse despite quiescent disease for a prolonged period. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. HUS and TTP: traversing the disease and the age spectrum.
- Author
-
Donadelli, Roberta, Sinha, Aditi, Bagga, Arvind, Noris, Marina, and Remuzzi, Giuseppe
- Subjects
THROMBOTIC thrombocytopenic purpura ,HEMOLYTIC-uremic syndrome ,AGE factors in disease ,SYMPTOMS ,BLOOD coagulation disorders ,DELAYED diagnosis - Abstract
Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenia purpura (TTP) are rare diseases sharing a common pathological feature, thrombotic microangiopathy (TMA). TMA is characterized by microvascular thrombosis with consequent thrombocytopenia, microangiopathic hemolytic anemia and/or multiorgan dysfunction. In the past, the distinction between HUS and TTP was predominantly based on clinical grounds. However, clinical presentation of the two syndromes often overlaps and, the differential diagnosis is broad. Identification of underlying pathogenic mechanisms has enabled the classification of these syndromes on a molecular basis: typical HUS caused by Shiga toxin-producing Escherichia coli (STEC-HUS); atypical HUS or complement-mediated TMA (aHUS/CM-TMA) associated with genetic or acquired defects leading to dysregulation of the alternative pathway (AP) of complement; and TTP that results from a severe deficiency of the von Willebrand Factor (VWF)-cleaving protease, ADAMTS13. The etiology of TMA differs between pediatric and adult patients. Childhood TMA is chiefly caused by STEC-HUS, followed by CM-TMA and pneumococcal HUS (Sp-HUS). Rare conditions such as congenital TTP (cTTP), vitamin B12 metabolism defects, and coagulation disorders (diacylglycerol epsilon mutation) present as TMA chiefly in children under 2 years of age. In contrast secondary causes and acquired ADAMT13 deficiency are more common in adults. In adults, compared to children, diagnostic delays are more frequent due to the wide range of differential diagnoses. In this review we focus on the three major forms of TMA, STEC-HUS, aHUS and TTP, outlining the clinical presentation, diagnosis and management of the affected patients, to help highlight the salient features and the differences between adult and pediatric patients which are relevant for management. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Characterization of genetic predisposition and autoantibody profile in atypical haemolytic–uraemic syndrome.
- Author
-
Gurjar, Bahadur Singh, Manikanta Sriharsha, Tholu, Bhasym, Angika, Prabhu, Savit, Puraswani, Mamta, Khandelwal, Priyanka, Saini, Himanshi, Saini, Savita, Verma, Anita Kamra, Chatterjee, Priyadarshini, Guchhait, Prasenjit, Bal, Vineeta, George, Anna, Rath, Satyajit, Sahu, Arvind, Sharma, Amita, Hari, Pankaj, Sinha, Aditi, and Bagga, Arvind
- Subjects
HEMOLYTIC-uremic syndrome ,REVERSE transcriptase polymerase chain reaction ,AUTOANTIBODIES ,GENOTYPES ,POLYANIONS - Abstract
Summary: We previously reported that Indian paediatric patients with atypical haemolytic–uraemic syndrome (aHUS) showed high frequencies of anti‐complement factor H (FH) autoantibodies that are correlated with homozygous deletion of the genes for FH‐related proteins 1 and 3 (FHR1 and FHR3) (FHR1/3
–/– ). We now report that Indian paediatric aHUS patients without anti‐FH autoantibodies also showed modestly higher frequencies of the FHR1/3–/– genotype. Further, when we characterized epitope specificities and binding avidities of anti‐FH autoantibodies in aHUS patients, most anti‐FH autoantibodies were directed towards the FH cell‐surface anchoring polyanionic binding site‐containing C‐terminal short conservative regions (SCRs) 17–20 with higher binding avidities than for native FH. FH SCR17–20‐binding anti‐FH autoantibodies also bound the other cell‐surface anchoring polyanionic binding site‐containing region FH SCR5–8, at lower binding avidities. Anti‐FH autoantibody avidities correlated with antibody titres. These anti‐FH autoantibody characteristics did not differ between aHUS patients with or without the FHR1/3–/– genotype. Our data suggest a complex matrix of interactions between FHR1‐FHR3 deletion, immunomodulation and anti‐FH autoantibodies in the aetiopathogenesis of aHUS. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations.
- Author
-
Thergaonkar, R. W., Narang, Ankita, Gurjar, Bahadur Singh, Tiwari, Pradeep, Puraswani, Mamta, Saini, Himanshi, Sinha, Aditi, Varma, Binuja, Mukerji, Mitali, Hari, Pankaj, and Bagga, Arvind
- Subjects
HEMOLYTIC-uremic syndrome ,GENETICS of disease susceptibility ,DNA copy number variations ,EXOMES ,NUCLEOTIDE sequencing ,GENETICS - Abstract
Background: Genetic susceptibility to atypical hemolytic uremic syndrome (aHUS) may lie within genes regulating or activating the alternate complement and related pathways converging on endothelial cell activation.Methods: We tested 32 Indian patients of aHUS negative for antibodies to complement factor H for genetic variations in a panel of 15 genes, i.e., CFH, CFHR1-5, CFI, CFB, C3, CD46, MASP2, DGKE, ADAMTS13, THBD and PLG using next-generation DNA sequencing and for copy number variation in CFHR1-3.Results: Despite absence of a public database of exome variations in the Indian population and limited functional studies, we could establish a genetic diagnosis in 6 (18.8%) patients using a stringent scheme of prioritization. One patient carried a likely pathogenic variation. The number of patients carrying possibly pathogenic variation was as follows: 1 variation: 5 patients, 2 variations: 9 patients, 3 variations: 5 patients, 4 variations: 9 patients, 5 variations: 2 patients and 6 variations: 2 patients. Homozygous deletion of CFHR1-3 was present in five patients; none of these carried a diagnostic genetic variation. Patients with or without diagnostic variation did not differ significantly in terms of enrichment of genetic variations that were rare/novel or predicted deleterious, or for possible environmental triggers.Conclusion: We conclude that genetic testing for multiple genes in patients with aHUS negative for anti-FH antibodies reveals multiple candidate variations that require prioritization. Population data on variation frequency of the Indian population and supportive functional studies are likely to improve diagnostic yield. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome.
- Author
-
Bhatia, Divya, Khandelwal, Priyanka, Sinha, Aditi, Hari, Pankaj, Cheong, Hae, and Bagga, Arvind
- Subjects
HEMOLYTIC-uremic syndrome ,SIBLINGS ,FLOW cytometry ,GENE expression ,GENETIC mutation ,POLYMERASE chain reaction ,RESEARCH funding ,DENGUE hemorrhagic fever ,FAMILY history (Medicine) ,DATA analysis software ,DESCRIPTIVE statistics ,SEQUENCE analysis ,GENETICS - Abstract
Background: Hemolytic uremic syndrome (HUS) secondary to homozygous mutations in CD46 is uncommon. While heterozygous individuals may remain asymptomatic, homozygous mutations with severely depleted CD46 surface expression without disease manifestation is rare. Methods: We report on two siblings with features suggestive of hemolytic uremic syndrome. Estimation of CD46 expression by flow cytometry and gene sequencing were performed in members of this family. Results: Three siblings, two of whom were symptomatic, had markedly decreased (<10 %) cell surface expression of CD46 and homozygous splice site mutation (IVS2 + 2 T > G) in the CD46 gene; the other 10-year-old sibling was asymptomatic. The illness was preceded by dengue shock syndrome in the index case. Both parents and two other siblings were heterozygous for this CD46 mutation. Conclusions: Homozygous IVS2 + 2 T > G mutation in CD46 gene, similar to heterozygous mutation, may be clinically silent at least during childhood. The role of antecedent infections in triggering the disease requires further examination. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. 43 Evaluation of iptacopan in atypical hemolytic uremic syndrome: Design and rationale of the Phase 3 open-label multicenter APPELHUS study.
- Author
-
Kavanagh, David, Greenbaum, Larry, Bagga, Arvind, Chen, Chien-Wei, Karki, Rajeshri, Vasudevan, Sajita, Charney, Alan, Dahlke, Marion, and Fakhouri, Fadi
- Subjects
- *
HEMOLYTIC-uremic syndrome - Published
- 2023
- Full Text
- View/download PDF
24. Anti-complement-factor H-associated glomerulopathies.
- Author
-
Durey, Marie-Agnes Dragon, Sinha, Aditi, Togarsimalemath, Shambhuprasad Kotresh, and Bagga, Arvind
- Subjects
- *
COMPLEMENT factor H , *HEMOLYTIC-uremic syndrome , *ACUTE kidney failure , *AUTOANTIBODIES , *IMMUNOSUPPRESSION - Abstract
Atypical haemolytic uraemic syndrome (aHUS), an important cause of acute kidney injury, is characterized by dysregulation of the complement pathway, frequent need for dialysis, and progression to end-stage renal disease. Autoantibodies against complement factor H (FH), the main plasma regulatory protein of the alternative pathway of the complement system, account for a considerable proportion of children with aHUS. The autoantibodies are usually associated with the occurrence of a homozygous deletion in the genes encoding the FH-related proteins FHR1 and FHR3. High levels of autoantibodies, noted at the onset of disease and during relapses, induce functional deficiency of FH, whereas their decline, in response to plasma exchanges and/or immunosuppressive therapy, is associated with disease remission. Management with plasma exchange and immunosuppression is remarkably effective in inducing and maintaining remission in aHUS associated with FH autoantibodies, whereas terminal complement blockade with eculizumab is considered the most effective therapy in other forms of aHUS. Anti-FH autoantibodies are also detected in a small proportion of patients with C3 glomerulopathies, which are characterized by chronic glomerular injury mediated by activation of the alternative complement pathway and predominant C3 deposits on renal histology. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.